Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,902 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07619521RecruitingPhase 1/Phase 2
Combination drug therapy for advanced pancreatic cancer
This trial tests two targeted drugs, selumetinib and DS-8201a (trastuzumab deruxtecan), for advanced pancreatic cancer that has spread or cannot be removed. The combination may help people whose tumors have specific markers (KRAS mutation and HER2 positivity).
New Haven, ConnecticutAges 18 years+ - NCT07617493RecruitingPhase 1/Phase 2
ICP-B208 for Advanced Solid Tumors
This early-stage trial tests a new cancer drug called ICP-B208 in people with advanced solid tumors (like stomach, colon, or other cancers) that have spread or cannot be removed surgically and have not responded to previous treatments. The study aims to find the right dose and see how well the drug works.
Beijing, Beijing MunicipalityAges 18–75 - NCT07617727RecruitingPhase 1
A study of an experimental drug for advanced solid tumors
This trial tests a new drug, JSKN021, for people with advanced solid tumors that have not responded to standard treatments, are not tolerated to them, or have no standard options. The goal is to see if the drug is safe and effective in treating these cancers.
Fuzhou, FujianAges 18–75 - NCT07618260RecruitingPhase 1
Testing SIM0613 in advanced solid tumors
This is an early-stage trial testing a new drug called SIM0613 for advanced cancers that have spread or grown despite other treatments. The drug is designed to target cancer cells using a special delivery system.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07612891RecruitingPhase 1/Phase 2
Testing INV-6452 for advanced breast cancer and solid tumors
This study tests a new drug called INV-6452 to see if it is safe and can help control advanced cancers that have grown despite prior treatment. The drug targets specific cancer cell weaknesses, particularly in hormone-sensitive breast cancers without HER2 mutations.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06708858RecruitingPhase 2
Studying surufatinib with chemo and immunotherapy for advanced bile duct cancer
This trial tests a combination of a targeted therapy (surufatinib), chemotherapy (gemcitabine and cisplatin), and an immunotherapy (durvalumab or pembrolizumab) for people with advanced bile duct cancer that hasn't been treated with systemic therapy before. The goal is to see if this combination can shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT07604571RecruitingPhase 1
Testing IEV407 for Advanced Hormone-Sensitive Breast Cancer
This study tests a new drug called IEV407, either alone or combined with existing hormone therapies, in people with advanced breast cancer that is hormone-receptor positive and HER2 negative. The trial aims to find the right dose and see if this combination helps people whose cancer has stopped responding to previous treatments.
New Haven, ConnecticutAges 18 years+ - NCT07605962RecruitingPhase 1/Phase 2
UI-102 treatment for advanced cancer
This early-stage trial tests a new drug called UI-102 in people with advanced cancer. Researchers want to see if it is safe and whether it can help shrink tumors in patients who have already tried standard treatments.
Dallas, TexasAges 18 years+ - NCT07607678RecruitingPhase 1
Testing BI 3819026 Alone and With Ezabenlimab for Advanced Cancer
This early-stage study tests whether a new drug called BI 3819026, alone or combined with another drug called ezabenlimab, is safe and well-tolerated in people whose advanced solid tumors have stopped responding to standard treatments. The goal is to find the right dose and understand how the drugs work in your body.
New Haven, ConnecticutAges 18 years+ - NCT07607054RecruitingPhase 1
EMB-15 for advanced solid tumors without standard treatment
This is a first-time-in-humans study testing a new drug called EMB-15 for patients with advanced cancers that have spread or cannot be surgically removed. The drug targets proteins called ALPP/ALPG, which may help your immune system fight cancer cells.
Guangzhou, GuangdongAges 18 years+ - NCT07605182Recruiting
Sperm Sorting Device to Improve IVF Success in Older Fathers
This study tests whether a special device that selects the most active sperm can improve IVF success rates when the male partner is 40 or older. The goal is to see if this sorting technique, combined with genetic testing of embryos, leads to healthier pregnancies.
Hà Nội, Ha DongAges 40 years+ - NCT07611903Recruiting
Oxygen delivery methods during endoscopy procedure
This trial compares two different ways of delivering oxygen through your nose during an endoscopy procedure (ERCP, which examines your bile ducts and pancreas). The study tests whether one method keeps your oxygen levels safer or more comfortable than the other.
Kocaeli, UmuttepeAges 18–84 - NCT07607119Recruiting
PULSAR radiation plus immunotherapy for advanced gastric cancer
This trial tests combining PULSAR (a type of radiation therapy) with immunotherapy drugs to treat gastric (stomach) cancer that cannot be surgically removed. You must have already completed at least 3 months of chemotherapy with immunotherapy and shown no cancer growth to qualify.
Seoul, Select Province/StateAges 19 years+ - NCT07611825RecruitingPhase 2
Gut Bacteria Treatment for Advanced Kidney Cancer Resistant to Immunotherapy
This study tests whether modifying your gut bacteria can help immunotherapy work again in advanced kidney cancer that has stopped responding to initial immune-checkpoint inhibitor treatment. Researchers will give you a special bacterial preparation along with a new immunotherapy drug to see if this combination can slow or shrink your cancer.
Nanjing, JiangsuAges 18–90 - NCT06302062RecruitingPhase 1
Using lymph node T cells for advanced solid tumors
This trial tests a new treatment using T cells taken from your lymph nodes to fight advanced solid tumors that have not responded to standard therapies. The goal is to see if this approach can help shrink tumors or slow their growth.
Guangzhou, GaungdongAges 18–75 - NCT06644430Recruiting
Burning lung spots plus systemic therapy for liver cancer
This trial tests whether burning away a few cancer spots in the lungs (called ablation) can help people with liver cancer who are already on a systemic treatment. If you have stable liver cancer and only a few lung spots that haven't grown, you may be eligible.
Beijing, Beijing MunicipalityAges 18–80 - NCT07597629RecruitingPhase 2
SYS6023 combination therapy for advanced breast cancer
This trial tests a new drug combination (SYS6023) for advanced breast cancer that has spread or cannot be surgically removed. The treatment targets a protein called HER3, which may help stop cancer growth in patients whose cancer has progressed despite previous treatments.
Harbin, HeilonjiangAges 18 years+ - NCT07601334RecruitingPhase 1
Testing HF50 safety in advanced solid tumors
This Phase 1 trial tests a new drug called HF50 in people with advanced cancers that have spread or cannot be surgically removed. The goal is to see if HF50 is safe and whether it helps shrink tumors in patients whose cancer has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07596693RecruitingPhase 1
KXV01 injection for advanced solid tumors
This early-stage trial tests KXV01, a personalized cancer treatment made from your own immune cells, for advanced solid tumors that have not responded to standard treatment. The goal is to see if it can help control your cancer and learn about its safety.
ShanghaiAges 18–70 - NCT07601243RecruitingPhase 1
GS-2426 for advanced solid tumors with MTAP deficiency
This study tests a new drug called GS-2426 for people with advanced solid tumors that have a specific genetic change called MTAP deficiency. It may be an option if other treatments have stopped working or are not available.
Boston, MassachusettsAges 18 years+ - NCT07602842RecruitingPhase 1/Phase 2
Testing IDP-001 for advanced solid tumors
This early-stage trial tests a new drug called IDP-001 in people with advanced cancers that have spread or cannot be surgically removed. The study aims to find the right dose and see how well the drug works against various solid tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT07595172RecruitingPhase 1/Phase 2
New drug combination for advanced pancreatic cancer
This study tests whether combining three treatments—NALIRIFOX (chemotherapy), Adebrelimab (an immune-boosting antibody), and PULSAR (radiation)—can help people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if this combination works better than standard care.
Chengdu, SichuanAges 18–75 - NCT07602907RecruitingPhase 2
Low-dose paclitaxel with immunotherapy for advanced HER2-negative breast cancer
This trial tests a combination of low-dose oral paclitaxel (a chemotherapy pill taken regularly) plus immunotherapy to treat advanced breast cancer that doesn't have high levels of HER2 protein. The goal is to slow or shrink tumors while managing side effects better than traditional high-dose chemotherapy.
Hangzhou, ZhejiangAges 18 years+ - NCT07600164RecruitingPhase 4
Real-world study of pyrotinib treatment for advanced HER2-positive breast cancer
This study follows patients with advanced breast cancer that has a protein called HER2 to see how well pyrotinib (a targeted drug) works when used in routine clinical practice. You'd be tracked over time to understand how this treatment affects your cancer and quality of life.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,902 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.